Project Medical

Harry (Heping) Meng

Ph.D. E-mail:harrymeng@yahoo.com17 Boice Lane, Belle Mead, NJ 08502

908-***-**** (H) / 908-***-**** (C)

Objective: Looking for a position of in vivo cardiovascular safety pharmacology in a

pharmaceutical/CRO company. Available immediately. Willing to relocate.Highlights:

In vivo cardiovascular pharmacologist with 15-year experience in US pharmaceutical

industry.

Highly trained in leading, designing and coordinating in vivo cardiovascular and safety

pharmacology studies (echocardiography, telemetry, BP, ECG, and cardiac function).

Superb skills and extensive knowledge in surgical intervention in creating animal models

for drug discovery and preclinical drug safety evaluations.

Expert in lab instrumentation and computerized data acquisition systems.

Led ECG operations for GLP toxicology studies (software validation, data acquisition, ECG

review, diagnosis, and report).

Working experience

2000-2012: Sr. Manager in charge of Cardiovascular Safety Pharmacology Lab and ECG

toxicology operations, Preclinical Safety, Sanofi, NJ

1997-2000: Research Scientist in charge of Ischemic Heart Diseases Lab

Cardiovascular Drug Discovery, Rhone-Poulenc Rorer, PA.

Education:

1995-1997: Postdoctoral fellow (Molecular Cardiology Section), National Institutes of

Health, Bethesda, MD

1992-1995: Postdoctoral Fellow (Cardiovascular Pharmacology Lab), Dept. Pharmacology,

University of Ottawa, Canada.

1987-1992: Ph. D. (Cardiovascular Physiology Lab), Department of Physiology,

University of Manitoba, Canada.

1980-1983: M. Sc. (Cardiovascular Pharmacology Lab), Dept. Pharmacology, Beijing

University Medical School, China.

1973-1976: M. D. (Medicine), Beijing University Medical School, China.

Experience in Safety Pharmacology Studies:

Twelve-year experience of in vivo cardiovascular safety pharmacology. Fifteen-year

experience in cardiovascular research in US pharmaceutical industry.

Oversaw Cardiovascular Safety Lab for non-GLP safety pharmacology studies to evaluate

cardiovascular risks for novel compounds (BP/HR, cardiac function, and echocardiography)

in support of discovery and pre-clinical drug safety evaluations.

Served as a project team representative for different projects for drug safety profiling.

Organized battery of the drug safety tests (cardiovascular, hERG and Irwin) for novel

compounds. Set up collaborations and proposed appropriate safety tests.

Planned/organized in vivo cardiovascular studies, performed animal surgeries, acquired

and analyzed data, and drafted reports. Presented results in project team meetings on a

regular basis.

Served as an internal consultant for ECG, QT, and cardiovascular safety issues.

Directly involved in ECG acquisition, analysis, interpretation and reporting. Focused on

compounds with issues of potential QT prolongation. Closely interacted with

electrophysiology lab and PK group for addressing the QT issue. Reviewed CRO reports,

study design, and data interpretation. Highly experienced in QT correction formulas.

Modified QT correction formula for internal use.

Supervised 1-5 lab technicians, including daily duty assignment, goal setting and

performance reviews, and training on surgery and/or computerized data acquisition.

Experience with in vivo animal models:

Thirty-two-year experience of in vivo cardiovascular pharmacology. Hands on experiences

in animal surgery. Performed surgeries on rats, dogs, minipigs, rabbits, and guinea-pigs.

Excellent surgical skills, such as telemetry radio transmitter implantation in dogs,

rats, and guinea-pigs. Performed open-chest operations in mini-pigs and rats with multiple

catheterizations and blood flow measurement.

Played a leading role in animal model development, validation and optimization throughout

my pharmaceutical career. Led the establishment of the following animal models:Telemetry/Echocardiography model in anesthetized rats (Cardiac function, BP/HR/ECG)

Telemetric dogs (BP and ECG)

Telemetric rats (BP/HR)

Telemetric mice (Core body temperature and activity)

Telemetric rabbits (BP/HR)

Colonic pressure in anesthetized rats (Colonic pressure, BP/HR)

Catheterized conscious rats (BP/HR)

Expert on software programming, hardware upgrading and computerized data acquisition.

Highly skilled in using telemetric/hemodynamic data acquisition (DSI Gould/Ponemah) for

measurement of ECG, cardiac function and hemodynamics, such as cardiac output,

intraventricular pressure, dp/dt, coronary blood flow, heart rate and blood pressure.Experience in GLP Studies:

Played a leading role in ECG operations for GLP toxicology studies in dogs.

Validated Ponemah software for dog ECG recording and analysis (GLP). Established the

entire work flow. Managed data collection, analysis, and storage. Responsible for ECG

diagnosis and phase reports for all dog ECG studies.

Developed SOPs and user guides. Trained personnel for ECG collections (GLP). Performed

system maintenance.

Computer Skills:

Gould/Ponemah data acquisition system (Set up and programming)

DSI telemetric device (Set up and programming).

Statistical analysis and graphic composition (SigmaStat, Prism).

Previous Research Experience:

Research Scientist (Rhone-Poulenc Rorer, PA, USA)

Supervised Ischemia Heart Disease Lab. Generated data to support the IND of a

cardiovascular drug and the clinical development of another anti-ischemic compound.

Evaluated many other anti-ischemic drugs in minipig and rat models of acute coronary

artery occlusion.

Postdoctoral Fellow (National Institute of Health, Bethesda, MD)

Expressed myosin X in Baculovirus/Sf9 cells using baculovirus, cell culture, subcloning,

PCR, restriction digestion, sequencing, DNA purification technologies. Purification of

myosin VII from bovine testis.

Postdoctoral Fellow (University of Ottawa, Ottawa, Canada)

Generated antibodies from rabbits. Research on the association of dystrophin with cardiac

myofibrils and copurification of DHP receptor and Na+-Ca2+ exchanger in cardiac muscle.

Western Blot analysis and immunoprecipitation.

Ph.D. Student (Dept. Physiology, Univ. Manitoba, Winnipeg, Canada)

Protective effect of 5-(N, N-dimethyl)amiloride and possible role of Na+-H+ exchange in

the development of ischemia-reperfusion injury in rat heart. Animal models of ischemic

heart failure and exercise (swimming and treadmill running). Isolation of cardiac

sarcolemma and characterization of sarcolemmal ion transport.

M.Sc. student (Dept. Pharmacology, Beijing Univ. Medical School, China)

Cardiovascular effects of a novel calcium antagonist, N-ethylperhexiline. Minor projects:

screening of anti-ischemic and anti-arrhythmic drugs with in vivo and in vitro animal

models.

Lecturer (Dept. Pharmacology, Beijing Univ. Medical School, China)

Taught Medical Pharmacology and Experimental Pharmacology. Evaluated cardiovascular

pharmacology of Chinese medicinal herbs.

Awards:

2004 Employee Spot Award Browns

2005 Special Achievement Award (IKK2 project)

2005 Special Achievement Award (DP project)

2006 Special Achievement Award (IKK2 project)

2007 Employee Spot Award Silver

2008 Special Achievement Award (SYK project)References:

Available upon request.Full Length Research Publications:

Meng, He-ping and Zhang, Bao-heng: Effect of effective components of Hong Hua (a Chinese

medicinal herb) on vascular perfusion of isolated rabbit organs. in Collection of Research

of Chinese Medicinal Herb (1980 1981). 1981; PP. 233 238 ed by Beijing Medical University.

(In Chinese).

Zhang, Bao-heng; Meng, He-ping et al: Effects of valariana officinalis L extract on

cardiovascular system. Acta Pharmaceutica Sinica 17(5):382 384, 1982 (In Chinese)

Zhang, Bao-heng; Wang, Tong and Meng, He-ping et al: Cardiovascular effects of extract of

flower of chrysauthemum indicum L. Journal of Chinese Medicinal Herbs 15(4):14 16, 1984

(In Chinese)

Meng, He-ping and Zhang, Bao-heng: Cardiovascular effects of N ethyl perhexiline maleate

in animals. Acta Pharmaceutica Sinica 20(6):401 404, 1985 (In Chinese with English

abstract)

Meng, He-ping and Zhang, Bao-heng: Calcium antagonistic action of N ethyl perhexiline

maleate. Acta Pharmacologica Sinica 7(3):239 243, 1986 (In Chinese with English abstract)

Contact this candidate